| | | |  | Last call: Applications are due tonight for STAT Madness, our annual bracketed competition in which colleges, universities, and institutions from across the country go head-to-head and compete to have their biomedical research named the best innovation of the year. Apply now. | | | | By Angus Chen Molly Ferguson for STAT Scientists are working on the next generation of CAR-T therapies — from armored CARs to controllable CARs — to combat cancer. Read More | | By Angus Chen Courtesy Fred Hutch/Robert Hood Biotech startup Affini-T Therapetuics aims to use engineered T-cell receptors, or TCRs, to target the source of cancerous cells. Read More | | By Ed Silverman Adobe A new study finds a so-called "skinny label" for a generic version of a pricey cancer drug cut costs for patients on the medicine. Read More | | Sponsor content by Bristol Myers Squibb The adjuvant treatment of melanoma: our latest promising research Science underscores the potential of immunotherapy in the adjuvant treatment of some forms of cancer when reducing the risk of disease recurrence is the goal. Researchers recently unveiled extended follow-up data from an immunotherapy clinical trial in the adjuvant treatment of melanoma, a disease which can be deadly in advanced stages. Learn more about key findings here. | | By H. Gilbert Welch and Barnett Kramer Jacqueline Larma/AP A bill in Congress would require Medicare to cover annual liquid biopsies for the early detection of cancer. That's a bad idea. Read More | |
No comments